Oric Pharmaceuticals Inc (ORIC) Stock Price, Quote & News

Company Profile

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 2...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 388 5600

Website: www.oricpharma.com

Address:

240 East Grand Avenue, 2nd Floor, South San Francisco, United States

_www_larval_com_ Jul. 29 at 3:12 PM

$ORIC has slipped -4% lower to -9% (~10Mv) a moment ago, 08/15 options, follow for more volatility.

0 · Reply

EMbull Jul. 8 at 10:06 PM

$ORIC take this with a grain of salt, but my mom is currently part of phase I ORIC-114 with multiple brain mets, bony mets and liver mets. since on ORIC, no new growth, no side effects and some tumors showing regression. ORIC 114 targets a subtype of lung CA seen in healthy, young non-smokers. Since ORIC is currently the only thing on planet able to keep my mom alive, I bought shares to show my support. Just sharing this as an n=1, but def exceeding all my expectations currently. cheers

1 · Reply

JarvisFlow Jul. 8 at 6:47 PM

Ladenburg Thalmann updates rating for ORIC Pharmaceuticals ( $ORIC ) to Buy, target set at 15.

0 · Reply

Quantumup Jul. 8 at 12:26 PM

Ladenburg Thalmann🏁 $ORIC Buy-$15. $PFE $ALPMY $AMGN $TNGX Ladenburg Thalmann said in its research report: "Initiating coverage of $ORIC with a Buy rating and $15 price target based on 1) emerging profile of the PRC2 inhibitor ORIC-944 as a potential fast-follower to mevrometostat in treatment AR-experienced mCRPC, 2) strategic pivot for development of ORIC-114 from 2nd-line exon 20 EGFR/HER2 tumors to the 1st-line representing a larger addressable population and opportunity to maximize clinical differentiation based on potential best-in-class CNS activity and 3) experienced management team with a track record of guiding targeted cancer drugs through clinical development."

0 · Reply

AnalyticaInvestor Jul. 4 at 11:04 AM

$DMRC $BITF $ORIC $USCB $RDUS Legal pressure, biotech promise, and quiet financial outperformance, this week’s market movers have it all. Digimarc and Bitfarms are under legal scrutiny but showing signs of life in trading volume. ORIC Pharmaceuticals is gaining attention with strong data from its cancer trial and a fresh $125 million financing. USCB Financial is quietly delivering solid earnings growth while Red Cat Holdings remains one to watch in the drone space. Read all the details in the latest Analytica Alpha. https://analyticainvestor.beehiiv.com/p/lawsuits-rallies-and-resilience-5-stocks-on-the-edge-a87f27372a1721fc

0 · Reply

TrendEdgeLogan Jun. 28 at 5:13 PM

$ORIC $740M mkt cap $XBI name, saw accumulation above the key $10 level last week as a director made an unplanned open market purchase of $263K in stock. - Pct of funds long at record highs and rising. - Short float high at 27.48%, but may have peaked as it loses steam recently. TrendEdge.app/asset/ORIC

0 · Reply

StockElementCorporation Jun. 24 at 12:48 PM

📓 Top Insider Buys $RZLT – 1.23M shares ($4.0M) $PLTR – 1.04M shares ($2.15M) $THAR – 337.8K shares ($500K) $THO – 3K shares ($256.2K) $ORIC – 26.6K shares ($249.7K) MBRX – 675.7K shares ($250K) MBRX – 270.3K shares ($100K)

0 · Reply

SK_Trading_Substack Jun. 11 at 2:53 PM

$AKRO $XGN $GSHD $ORIC $LOMA Today's most likely to have a big week.

0 · Reply

AnomalyDetective Jun. 7 at 2:00 PM

The Market Momentum Gauge signals turned positive in Week 18 and we have seen a sharp increase in MDA breakout gains with +99.57% YTD avg cumulative returns trading in the positive signals. Including $ORIC $BDTX $APPS $ALTS $PDYN and others we have had 12 selections gain over 20% and as high as +111% in less than a week in just the last 4 weeks. Additional free breakouts from the automated website available here: http://top.vmbreakouts.com New Week 24 MDA selections for next week: https://seekingalpha.com/mp/1201-value-momentum-breakouts/articles/6165533-june-mda-breakout-stocks-week-24-and-highlighted-top-gainers

0 · Reply

AnomalyDetective Jun. 6 at 1:51 PM

$PDYN +39.8% $ALTS +36.9% from Week 22 still flying high with this Week 23 MDA picks up +10.8% led by $ORIC and $BDTX as the $LABU breakout takes off for the Active #ETF sector portfolio +32.3% YTD. Credit: http://vmbreakouts.com with free breakout picks at http://top.vmbreakouts.com

0 · Reply

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 29, 2025, 11:15 AM EDT - 2 months ago

ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital

May 28, 2025, 4:05 PM EDT - 2 months ago

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

May 28, 2025, 4:05 PM EDT - 2 months ago

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

May 27, 2025, 4:30 PM EDT - 2 months ago

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

May 27, 2025, 8:00 AM EDT - 2 months ago

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

May 5, 2025, 4:05 PM EDT - 3 months ago

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

Apr 28, 2025, 4:30 PM EDT - 3 months ago

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 22, 2025, 9:15 AM EDT - 3 months ago

ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech

Mar 25, 2025, 4:30 PM EDT - 4 months ago

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Feb 25, 2025, 4:15 PM EST - 5 months ago

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

Feb 18, 2025, 4:05 PM EST - 5 months ago

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

Jan 13, 2025, 8:05 AM EST - 7 months ago

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

Jan 6, 2025, 4:15 PM EST - 7 months ago

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 4:30 PM EST - 7 months ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Nov 1, 2024, 4:30 PM EDT - 9 months ago

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 9, 2024, 4:15 PM EDT - 10 months ago

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Aug 26, 2024, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 12, 2024, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

Aug 5, 2024, 4:15 PM EDT - 1 year ago

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

Jul 17, 2024, 1:00 PM EDT - 1 year ago

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

Jul 16, 2024, 4:59 PM EDT - 1 year ago

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

May 6, 2024, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

Apr 15, 2024, 4:15 PM EDT - 1 year ago

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

Apr 8, 2024, 8:00 AM EDT - 1 year ago

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 13, 2024, 8:19 AM EDT - 1 year ago

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

Mar 11, 2024, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

Mar 6, 2024, 4:30 PM EST - 1 year ago

ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 4:30 PM EST - 1 year ago

ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Feb 14, 2024, 4:30 PM EST - 1 year ago

ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

Jan 22, 2024, 8:30 AM EST - 1 year ago

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

Jan 8, 2024, 8:30 AM EST - 1 year ago

ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

Jan 2, 2024, 4:30 PM EST - 1 year ago

ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

$Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development$

Dec 11, 2023, 12:00 PM EST - 1 year ago

Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development

Dec 9, 2023, 8:00 AM EST - 1 year ago

ORIC Pharma NSCLC Brain Metastasis Data Is Highly Interesting

Nov 6, 2023, 4:10 PM EST - 1 year ago

ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

Nov 2, 2023, 9:00 AM EDT - 1 year ago

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Oct 21, 2023, 7:30 AM EDT - 1 year ago

Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

Oct 17, 2023, 4:30 PM EDT - 1 year ago

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

Sep 20, 2023, 4:30 PM EDT - 2 years ago

ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference

Aug 10, 2023, 4:05 PM EDT - 2 years ago

ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

Jul 27, 2023, 3:57 PM EDT - 2 years ago

You can still run with the stock market's bulls, but watch the exits

CCL CRON EEM EW KOPN PFG PRU

Jun 26, 2023, 8:30 AM EDT - 2 years ago

ORIC Pharmaceuticals Announces $85 Million Private Placement Financing

May 31, 2023, 4:10 PM EDT - 2 years ago

ORIC Pharmaceuticals to Participate in the Jefferies Healthcare Conference

May 8, 2023, 4:05 PM EDT - 2 years ago

ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

Apr 25, 2023, 4:30 PM EDT - 2 years ago

ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference

Apr 18, 2023, 4:15 PM EDT - 2 years ago

ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Mar 16, 2023, 4:05 PM EDT - 2 years ago

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates

Mar 15, 2023, 12:47 AM EDT - 2 years ago

ORIC Pharma: Small Pfizer Deal, Cash, And A Set Of Very Early Stage Assets

Mar 14, 2023, 4:30 PM EDT - 2 years ago

ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting

_www_larval_com_ Jul. 29 at 3:12 PM

$ORIC has slipped -4% lower to -9% (~10Mv) a moment ago, 08/15 options, follow for more volatility.

0 · Reply

EMbull Jul. 8 at 10:06 PM

1 · Reply

JarvisFlow Jul. 8 at 6:47 PM

Ladenburg Thalmann updates rating for ORIC Pharmaceuticals ( $ORIC ) to Buy, target set at 15.

0 · Reply

Quantumup Jul. 8 at 12:26 PM

0 · Reply

AnalyticaInvestor Jul. 4 at 11:04 AM

0 · Reply

TrendEdgeLogan Jun. 28 at 5:13 PM

0 · Reply

StockElementCorporation Jun. 24 at 12:48 PM

0 · Reply

SK_Trading_Substack Jun. 11 at 2:53 PM

$AKRO $XGN $GSHD $ORIC $LOMA Today's most likely to have a big week.

0 · Reply

AnomalyDetective Jun. 7 at 2:00 PM

0 · Reply

AnomalyDetective Jun. 6 at 1:51 PM

0 · Reply

Rounderssss4 Jun. 4 at 2:30 PM

$ORIC

0 · Reply

metalcook Jun. 2 at 1:44 PM

$ORIC how does this compare to $JANX and $VIR?

1 · Reply

GSP Jun. 2 at 1:00 PM

Video title should say June 2nd, not the 1st. Apologies. $SPY $RRGB $ORIC $TNGX $LTBR

0 · Reply

leon_dedrick May. 30 at 6:39 PM

$ORIC This will quietly creep over 10.00 the next month

0 · Reply

GSP May. 30 at 11:34 AM

$SPY $ZEO $ORIC $U $SGBX

0 · Reply

PaulLaurent May. 30 at 5:48 AM

4:00am EST Watchlist 🌅 part two $INAB – AH runner catching volume after recent lows. Traders watching for continuation in early premarket. 🚀 $PATH – UiPath reported Q1 fiscal 2026 revenue of $ 335M, up 16% YoY. Beat EPS and raised FY guidance. AI theme keeps it in play. 🤖📈 $SPRO – Speculative biotech with recent upside momentum. Potential for multi-day continuation if volume sustains. 🧬 $ORIC – On watch after multiple updates this week including new private placement and promising clinical data. 🔬💰 $ZEO – Recent acquisition of Heliogen still in focus. Traders watching for clean setup following news digestion. ☀️ 📉 Market tone: Eyes on tech and biotech catalysts. Expect early volatility if momentum builds off AH action.

0 · Reply

StocktwitsNews May. 30 at 3:59 AM

Oric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer Trial $ORIC https://stocktwits.com/news/equity/markets/oric-pharma-stock-hits-3-month-high-on-promising-results-in-prostate-cancer-trial/ch0M1zSRbMf

0 · Reply

fallondpicks May. 29 at 9:30 PM

22 #stockbreakouts $AI (gap and base), $ORIC (gap), $SPTN (base), $VEEV (gap). Five sub-$1.

1 · Reply

hiloSF May. 29 at 7:08 PM

"8 Trading Tips for Gap Up Stocks: Understanding Stock Chart Technical Analysis and Trading Strategies" 🐸🐾 👉 https://dreamchaserx.com/8-trading-tips-for-gap-up-stocks $STUDY $ELF $BBW $ZEO $ORIC #swingtradingstrategy #stockchartanalysis #tradingtips #howtotradestocks #StockWatch

0 · Reply

SelectiveTrader May. 29 at 6:00 PM

Good afternoon, my afternoon day trade watch list part 2: $IMNN $MLGO $SBET $WETO $ORIC

0 · Reply

DARKP00L May. 29 at 5:54 PM

$ORIC 13:52 on May. 29 2025 Oric Pharmaceuticals shares are trading higher after the company reported positive efficacy and safety data from its early-stage prostate cancer candidate and announced a $125 million private placement. #tradeideas

0 · Reply

Market Cap	940.87M
Revenue (ttm)	0.00
Net Income (ttm)	-127.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	882,400
Avg Vol	1,531,478
Day's Range	N/A - N/A
Shares Out	85.22M
Stochastic %K	36%
Beta	1.54
Analysts	Strong Sell
Price Target	$18.55